Meta-Analysis on the Effect of Contingency Management for Patients with Both Psychotic Disorders and Substance Use Disorders.
contingency management
psychosis
substance use disorder
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
06 Feb 2021
06 Feb 2021
Historique:
received:
26
12
2020
revised:
27
01
2021
accepted:
03
02
2021
entrez:
10
2
2021
pubmed:
11
2
2021
medline:
11
2
2021
Statut:
epublish
Résumé
Substance use disorders (SUD) are highly prevalent among psychotic patients and are associated with poorer clinical and functional outcomes. Effective interventions for this clinical population are scarce and challenging. Contingency management (CM) is one of the most evidence-based treatments for SUD's, however, a meta-analysis of the effect of CM in patients with a dual diagnosis of psychotic disorder and SUD has not been performed. We searched PubMed and PsycINFO databases up to December 2020. Five controlled trials involving 892 patients were included. CM is effective on abstinence rates, measured by the number of self-reported days of using after intervention (95% CI -0.98 to -0.06) and by the number of negative breath or urine samples after intervention (OR 2.13; 95% CI 0.97 to 4.69) and follow-up (OR 1.47; 95% CI 1.04 to 2.08). Our meta-analysis shows a potential effect of CM on abstinence for patients with SUD and (severe) psychotic disorders, although the number of studies is limited. Additional longitudinal studies are needed to confirm the sustained effectivity of CM and give support for a larger clinical implementation of CM within services targeting these vulnerable co-morbid patients.
Sections du résumé
BACKGROUND
BACKGROUND
Substance use disorders (SUD) are highly prevalent among psychotic patients and are associated with poorer clinical and functional outcomes. Effective interventions for this clinical population are scarce and challenging. Contingency management (CM) is one of the most evidence-based treatments for SUD's, however, a meta-analysis of the effect of CM in patients with a dual diagnosis of psychotic disorder and SUD has not been performed.
METHODS
METHODS
We searched PubMed and PsycINFO databases up to December 2020.
RESULTS
RESULTS
Five controlled trials involving 892 patients were included. CM is effective on abstinence rates, measured by the number of self-reported days of using after intervention (95% CI -0.98 to -0.06) and by the number of negative breath or urine samples after intervention (OR 2.13; 95% CI 0.97 to 4.69) and follow-up (OR 1.47; 95% CI 1.04 to 2.08).
CONCLUSIONS
CONCLUSIONS
Our meta-analysis shows a potential effect of CM on abstinence for patients with SUD and (severe) psychotic disorders, although the number of studies is limited. Additional longitudinal studies are needed to confirm the sustained effectivity of CM and give support for a larger clinical implementation of CM within services targeting these vulnerable co-morbid patients.
Identifiants
pubmed: 33561966
pii: jcm10040616
doi: 10.3390/jcm10040616
pmc: PMC7916027
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Perspect Behav Sci. 2019 Jun 26;42(3):479-499
pubmed: 31976446
Am J Psychiatry. 2017 Apr 1;174(4):370-377
pubmed: 28135843
J Dual Diagn. 2020 Jul 31;:1-9
pubmed: 32735514
Subst Abuse Treat Prev Policy. 2020 Sep 14;15(1):71
pubmed: 32928275
Neurosci Biobehav Rev. 2020 Jan;108:295-307
pubmed: 31778679
Harv Rev Psychiatry. 2009;17(1):24-34
pubmed: 19205964
Health Technol Assess. 2015 Jul;19(56):1-130
pubmed: 26202542
Drug Alcohol Depend. 2020 Nov 1;216:108307
pubmed: 33007699
Schizophr Res. 2011 Aug;130(1-3):228-33
pubmed: 21592731
Psychiatr Serv. 2005 Oct;56(10):1282-7
pubmed: 16215196
J Consult Clin Psychol. 2006 Jun;74(3):592-601
pubmed: 16822115
J Consult Clin Psychol. 2018 Oct;86(10):799-809
pubmed: 30265039
J Subst Abuse Treat. 2019 May;100:64-83
pubmed: 30898330
Addict Behav. 2009 Oct;34(10):806-14
pubmed: 19375237
Medicine (Baltimore). 2018 Dec;97(50):e13566
pubmed: 30558020
Psychopharmacology (Berl). 2011 Sep;217(2):279-87
pubmed: 21475970
Psychol Addict Behav. 2017 Dec;31(8):897-906
pubmed: 28639812
Curr Behav Neurosci Rep. 2016 Sep;3(3):232-247
pubmed: 27980891
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Clin Psychiatry. 2009 Mar;70(3):362-9
pubmed: 19284931
BMC Med Res Methodol. 2014 Dec 19;14:135
pubmed: 25524443
Br J Psychiatry. 2000 Apr;176:345-50
pubmed: 10827882
Behav Res Ther. 2021 Jan;136:103781
pubmed: 33302054
Addiction. 2006 Nov;101(11):1546-60
pubmed: 17034434
Cochrane Database Syst Rev. 2019 Dec 12;12:CD001088
pubmed: 31829430
BMJ Open. 2020 Oct 8;10(10):e034735
pubmed: 33033080
J Consult Clin Psychol. 2010 Feb;78(1):89-97
pubmed: 20099954
BMC Med. 2019 Aug 15;17(1):161
pubmed: 31412884
Front Psychiatry. 2015 Jun 01;6:76
pubmed: 26082725
Schizophr Res. 2004 Apr 1;67(2-3):157-66
pubmed: 14984874
Drug Alcohol Depend. 2018 Oct 1;191:234-258
pubmed: 30153606
Am J Psychiatry. 2013 Jan;170(1):94-101
pubmed: 23138961
Schizophr Res. 2010 Dec;124(1-3):22-8
pubmed: 20934306
Addiction. 2006 Feb;101(2):192-203
pubmed: 16445548
Addiction. 2006 Jan;101(1):50-9
pubmed: 16393191
Eval Health Prof. 2015 Mar;38(1):94-114
pubmed: 24695072
Front Psychiatry. 2019 May 22;10:311
pubmed: 31178763
Prev Med. 2016 Nov;92:36-46
pubmed: 27514250
Perspect Behav Sci. 2019 Jul 29;42(3):501-524
pubmed: 31976447
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Lancet Public Health. 2019 May;4(5):e229-e244
pubmed: 31054641
PLoS Med. 2018 Dec 26;15(12):e1002715
pubmed: 30586362
Drug Alcohol Depend. 2007 Mar 16;87(2-3):288-96
pubmed: 17005329
Addiction. 2014 Sep;109(9):1426-36
pubmed: 24750232
BMJ. 2011 Feb 10;342:d549
pubmed: 21310794
Subst Abuse Rehabil. 2018 Aug 13;9:43-57
pubmed: 30147392
BMC Psychiatry. 2014 Dec 02;14:343
pubmed: 25438877
Nicotine Tob Res. 2021 Jan 22;23(2):320-326
pubmed: 32772097
Am J Psychiatry. 2008 Feb;165(2):179-87
pubmed: 18198270
NPJ Schizophr. 2018 May 28;4(1):9
pubmed: 29808011